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Letter to the Editor
Response to Dr C. Daniel Mullins’ letter [re: Osteoarthritis and Cartilage,
2002; 10:518–27]
We are pleased that Dr Mullins found our study worthy of
applause, and one that fills a gap in available information
regarding therapeutic approaches to the management of
patients with knee OA. Indeed, the study was designed and
executed as rigorously as possible, and represents, in our
opinion, not only valuable scientific information for the
management of patients with knee OA, but also a useful
teaching example of good methodology for the design and
analysis of pragmatic, health outcomes, and cost-
effectiveness trials.
We also thank Dr Mullins for raising a number of ques-
tions and providing us the opportunity to respond.
Non-inclusion of COX-2 specific inhibitors
At the time of study initiation (1997), the new generation
of COX-2 specific inhibitors were not yet licensed for use in
North America. The ACR Guidelines which defined the
treatment paradigm for the appropriate care (AC) arm of
the study were those published in 19951.
We are happy to address the conjectural question raised
by Dr Mullins, regarding how the results of the study might
have changed if the currently available COX-2 specific
NSAIDs had been available at that time.
With respect to clinical effectiveness, we believe the
incremental improvement we observed for the appropriate
care+hylan G-F 20 (AC+H) arm might be expected to
persist had COX-2 specific agents been available during
our study. This speculation is based on the fact that COX-2
specific agents have not demonstrated improvement in
pain relief compared to generic NSAIDs2.
With respect to safety, it is possible that the statistically
significant and clinically important decrease in treatment-
related GI adverse events reported for the AC+H arm in our
trial might not have been observed had COX-2 specific
inhibitors been available during the study. However, be-
cause these two NSAID classes differ with respect to the
number and type of associated adverse events and the
debate continues regarding their overall safety profile and
drug interactions2,3, it is difficult, on balance, to predict how
the availability of these agents might have changed the
systemic safety outcomes of our study.
With respect to costs, we would expect that the mean
annual cost per patient would have increased more in the
AC arm than the AC+H arm. This conjecture is based on
the greater NSAID usage in the AC arm (p0.0062) of our
study and the higher acquisition costs of COX-2 specific
agents.
In summary, we speculate that the cost-effectiveness
and cost-utility of adding hylan G-F 20 to the treatment
paradigm would have at least remained comparable, and
might even have improved, had COX-2 specific agents
been available during our study.
Cost differences in cost categories
Dr Mullins is puzzled by the directions of the cost
differences in a number of cost categories. To this we have
two comments. First, the study was designed to measure
overall costs and compute overall cost-effectiveness and
cost-utility results. It was not designed or powered to
investigate cost differences at the level of cost categories.
To do so is akin to performing post hoc sub-group analyses
and has the same methodological weaknesses. That is, the
comparisons should be adjusted for multiple testing, and
any statistically significant results are, at best, hypothesis
generating.
Nevertheless, and second, we provide here some com-
ments and elaborations on these cost differences. Dr
Mullins noted that the group treated with hylan G-F 20
(AC+H) had lower costs of medications for knee OA (e.g.,
NSAIDs). This difference was substantial (46% lower) and
was presumably due to the beneficial effect of the hylan
G-F 20 treatment. In contrast, as Dr Mullins noted, the
group treated with hylan G-F 20 had higher costs of treating
adverse events due to OA treatment. This difference,
however, was slight (8% higher) and given the very large
standard deviations would not come close to approaching
statistical significance. Moreover, the details of this cost
category show it to be composed of a wide variety of
medications (23 different kinds of medications as coded by
anatomic therapeutic classification (major code) and by
drug indication (minor code) using the 1999 Compendium
of Pharmaceuticals and Specialties (CPS; Canadian Phar-
maceutical Association) and, the number of actual medi-
cations (i.e., drug treatments) for the AC+H group was 81
while that for the AC group was 86. Thus, we conclude that
the minor difference in this cost category was due to
chance, and is not a meaningful difference that deserves
an interpretation.
Dr Mullins notes that hospitalization costs were higher in
the treatment group. As we explained in the article this
came about because of our broad inclusion criteria for
relevant hospitalization costs. We included the costs of all
hospitalizations attributed to OA (in any joint). In the base
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case analysis there were a total of five patients requiring
hospitalization attributable to OA in the AC+H group and
three patients in the AC group. The five patients in the
AC+H group had: total knee replacement in the study knee,
total knee replacement in the other knee, total hip replace-
ment, triple ankle fusion, and tibia osteotomy. The three
patients in the AC group had: total knee replacement in
study knee, total knee replacement in other knee, and
bunionectomy. Interestingly, there were two additional hos-
pitalizations in the AC group (both representing total knee
replacements in the study knee) that were not counted in
the base case analysis because they occurred after the two
patients in question had violated protocol.
Finally, Dr Mullins notes that costs for essentially every
category of indirect costs (i.e., time lost from work and
transportation costs) were higher in the AC+H group. As we
explained in the article this was due to the visits needed for
the hylan G-F 20 injections.
Local AEs to hylan G-F 20
Dr Mullins raises safety concerns regarding local reac-
tions after the administration of hylan G-F 20. We would
point out that acute inflammatory reactions can occur with
all intra-articular treatments including hyaluronan4 and
corticosteroids5. Reports as to the prevalence of such
reactions vary widely6.
Dr Mullins cites a recent publication, which purports to
show that the rate of local reactions after hylan G-F 20
injection increases from 2 to 21% when comparing first and
second courses of treatment. This publication compares a
cohort of patients who received their first course of hylan
G-F 20 as part of a clinical trial, to an unrelated retrospec-
tive cohort who received their second course during routine
medical practice. Though we will not address the method-
ology used in this citation, we can comment on the preva-
lence of adverse reactions during repeat courses of hylan
G-F 20 treatment in our trial. Repeat treatment was permit-
ted by our study protocol because of its pragmatic design,
and was administered to 48 patients. These recently pre-
sented data7 found that the prevalence of local reactions
attributed to hylan G-F 20 by the investigators to be 1.7%
during first courses and 2.9% during second courses.
There was no statistically significant difference in the per-
centage of patients reporting local adverse reactions be-
tween the first course subgroup and the first course of
treatment in the second course subgroup. Similarly, there
was no statistically significant difference between the first
course of treatment and second course of treatment in the
second course subgroup.
In summary, we believe that our study provides data that
demonstrate the favorable risk–benefit relationship for
intra-articular injections of hylan G-F 20 compared to other
treatments for OA, during both first and second courses of
treatment. Though local reactions can and do occur, we
believe the safety of hylan G-F 20 compares favorably to
other available treatments for knee OA.
Costs associated with the management of
adverse reactions
Dr Mullins indicates that “It is not clear if Torrance and
colleagues have considered the potentially significant
medical costs associated with the management of these
adverse reactions in clinical practice and/or hospital set-
tings as well as the indirect costs of these adverse reac-
tions as part of the projected cost of hylan G-F 20 therapy”.
The answer is yes indeed, that is exactly what we consid-
ered. We apologize if the manuscript was not clear on that
point. Patients were instructed to report all health care
resource utilization and all time lost and expenses regard-
less of the health reason. Those attributable to OA, to the
treatment of OA, or to the side effects or adverse events of
the treatment of OA were included in the analysis.
We thank Dr Mullins for his interest in our work, and for
the opportunity to respond to his questions. We believe our
study definitively supports the 2000 revision of the ACR
guidelines8, which include intra-articular therapy with hylan
G-F 20 as part of the treatment paradigm for patients with
knee OA.
References
1. Hochberg MC, Altman RD, Brandt KD, Clark BM,
Dieppe PA, Griffin MR, et al. Guidelines for the medical
management of osteoarthritis. Part II. Osteoarthritis of
the knee. Arthritis Rheum 1995;38:1541–6.
2. United States Food and Drug Administration,
Center for Drug Evaluation and Research. CDER
new and generic drug approvals, 1998–2002.
Accessed October 12, 2002 at http://www.fda.gov/
cder/approval/index.htm.
3. Juni P, Rutjes AW, Dieppe PA. Are selective COX 2
inhibitors superior to traditional non steroidal anti-
inflammatory drugs? BMJ 2002;324(7349):1287–8.
4. Luzar MJ, Altawil B. Pseudogout following intra-articular
injection of sodium hyaluronate. Arthritis Rheum 1998;
41(5):939–40.
5. Gray RG, Tenenbaum J, Gottlieb NL. Local corticoster-
oid injection treatment in rheumatic disorders. Semin
Arthritis Rheum 1981;10(4):231–54.
6. Adams ME, Lussier AJ, Peyron JG. A risk–benefit
assessment of injections of hyaluronan and its deriva-
tives in the treatment of osteoarthritis of the knee. Drug
Saf 2000;23(2):115–30.
7. Raynauld JP, Bellamy N, Goldsmith CH, Tugwell P,
Torrance GW, Pericak D. et al. An evaluation of the
safety and effectiveness of repeat courses of hylan
G-F 20 for treating patients with knee osteoarthritis.
Osteoarthritis Research Society International, 2002
OARSI World Congress on Osteoarthritis, Sydney,
Australia [Paper reference # PS128].
8. American College of Rheumatology Subcommittee on
Osteoarthritis Guidelines. Recommendations for the
medical management of osteoarthritis of the hip and
knee. Arthritis Rheum 2000;43:1905–15.
G. W. Torrance
C. H. Goldsmith
Department of Clinical Epidemiology and
Biostatistics
McMaster University
Hamilton
Ontario
Canada
P. A. Band
Department of Pharmacology
New York University
380 G. W. Torrance et al.: Response to Dr C. Daniel Mullins’ letter
School of Medicine
New York
NY
USA
J. P. Raynauld
Department of Medicine
University of Montreal
Montreal
Quebec
Canada
G. W. Torrance
V. Walker
Innovus Research Inc.
Burlington
Ontario
Canada
N. Bellamy
Department of Medicine
University of Queensland
Queensland
Australia
M. Schultz
Pharmaccess Inc.
Montreal
Quebec
Canada
P. Tugwell
Department of Medicine
University of Ottawa
Ottawa
Ontario
Canada
Osteoarthritis and Cartilage Vol. 11, No. 5 381
